Cargando…

The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study

BACKGROUND: Low adherence to adjuvant tamoxifen is associated with worse health outcomes but little is known about the cost-effectiveness of high adherence. METHODS: We conducted an economic evaluation using data for all women with incident breast cancer between 1993 and 2000 who were subsequently p...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCowan, C, Wang, S, Thompson, A M, Makubate, B, Petrie, D J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778308/ https://www.ncbi.nlm.nih.gov/pubmed/23949153 http://dx.doi.org/10.1038/bjc.2013.464

Ejemplares similares

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
por: McCowan, C, et al.
Publicado: (2008)

Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
por: Makubate, B, et al.
Publicado: (2013)

Completion of 5-year adjuvant endocrine therapy in the community
por: Makubate, B, et al.
Publicado: (2010)

Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
por: Hind, D, et al.
Publicado: (2007)

Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer
por: Huiart, L, et al.
Publicado: (2011)

Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan
por: Kondo, M, et al.
Publicado: (2009)

Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic
por: Donnelly, L S, et al.
Publicado: (2014)

Myocardial infarction risk and tamoxifen therapy for breast cancer
por: Geiger, A M, et al.
Publicado: (2005)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
por: Hrstka, Roman, et al.
Publicado: (2013)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
por: Sestak, I, et al.
Publicado: (2012)

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram
por: Lash, T L, et al.
Publicado: (2008)

Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women
por: Thomas, R, et al.
Publicado: (2008)

Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
por: Park, Y, et al.
Publicado: (2009)

Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial
por: Mansel, R, et al.
Publicado: (2007)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
por: Hilborn, Erik, et al.
Publicado: (2016)

Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial
por: Yang, H, et al.
Publicado: (2013)

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
por: Hasan, J, et al.
Publicado: (2005)

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
por: Lammers, L A, et al.
Publicado: (2010)

Tamoxifen for women at high risk of breast cancer
por: Nazarali, Safia A, et al.
Publicado: (2014)

A cluster randomised stepped wedge trial to evaluate the effectiveness of a multifaceted information technology-based intervention in reducing high-risk prescribing of non-steroidal anti-inflammatory drugs and antiplatelets in primary medical care: The DQIP study protocol
por: Dreischulte, Tobias, et al.
Publicado: (2012)

Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen
por: Bychkovsky, Brittany, et al.
Publicado: (2022)

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
por: Munster, P N, et al.
Publicado: (2011)

Breast Cancer Treatment Practices in Elderly Women in a Community Hospital
por: Wang, Hua, et al.
Publicado: (2011)

Diagnostic accuracy systematic review of rectal bleeding in combination with other symptoms, signs and tests in relation to colorectal cancer
por: Olde Bekkink, M, et al.
Publicado: (2010)

Value of Procollagen Type I Aminoterminal Propeptide in Women with Breast Cancer with regard to Metastases
por: Clouth, A., et al.
Publicado: (2011)

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
por: Pfeiler, G, et al.
Publicado: (2013)

Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations
por: Duffy, S W, et al.
Publicado: (2002)

Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors
por: Uslu, Yasemin, et al.
Publicado: (2023)

Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy
por: Henry, N L, et al.
Publicado: (2010)

Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study
por: Fraser, D M, et al.
Publicado: (2014)

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
por: De Placido, S, et al.
Publicado: (2005)

Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients
por: Azria, D, et al.
Publicado: (2004)

Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
por: Lindemann, Kristina, et al.
Publicado: (2017)

Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Guideline adherence for early breast cancer before and after introduction of the sentinel node biopsy
por: Schaapveld, M, et al.
Publicado: (2005)

Effect of tamoxifen with or without gonadotropin-releasing hormone analog on DXA values in women with breast cancer
por: Kim, Eun Heui, et al.
Publicado: (2021)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Surveillance for endometrial cancer with transvaginal ultrasonography of breast cancer patients under tamoxifen treatment
por: Ciatto, S, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_07be9o540n60de8t86qcp8h6sk